---
title: "CSSD issued a profit warning, expecting a net profit of 639 million yuan for the fiscal year 2024, a year-on-year decrease of 53.08%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/225322555.md"
description: "According to the Zhitong Finance APP, CSSD has released its performance forecast for 2024. The company expects to achieve a net profit attributable to the owners of the parent company of 639 million yuan in 2024, a year-on-year decrease of 53.08%; it is expected to achieve a net profit attributable to the owners of the parent company after deducting non-recurring gains and losses of 566 million yuan in 2024, a year-on-year decrease of 51.92%"
datetime: "2025-01-17T09:19:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/225322555.md)
  - [en](https://longbridge.com/en/news/225322555.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/225322555.md)
generator: "portal-rs"
---

# CSSD issued a profit warning, expecting a net profit of 639 million yuan for the fiscal year 2024, a year-on-year decrease of 53.08%

According to the Zhitong Finance APP, CSSD (601512.SH) released its performance forecast for 2024, expecting a net profit attributable to the owners of the parent company of 639 million yuan, a year-on-year decrease of 53.08%; it is expected that the net profit attributable to the owners of the parent company, excluding non-recurring gains and losses, will be 566 million yuan, a year-on-year decrease of 51.92%

### Related Stocks

- [601512.CN](https://longbridge.com/en/quote/601512.CN.md)

## Related News & Research

- [Xiaomi sets September 7 launch for 18 Fold foldable phone](https://longbridge.com/en/news/297748864.md)
- [XPENG Sales Up 4% in August](https://longbridge.com/en/news/297713940.md)
- [Cleo Diagnostics to Commence Analytical Validation of Pre-Surgical Ovarian Cancer Blood Test](https://longbridge.com/en/news/297848437.md)
- [NeuroThera Labs seeks FDA orphan drug status for adult Tourette treatment SCI-110](https://longbridge.com/en/news/297783543.md)
- [BioVersys says FDA grants Fast Track designation for BV100 antibiotic candidate](https://longbridge.com/en/news/297733781.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**